Due to the surge in COVID-19 cases, respiratory medicines
are in high demand. Since early March, pharmacists have warned about a looming respiratory drug shortage.
Hand sanitizer is also in
short supply as people race
to stock up and protect themselves from getting sick.
Additionally, many businesses remain closed and will not
be able to reopen without
introducing policies to
protect their workforce’s
health, including on-site
Nephron Pharmaceuticals has stepped up its manufacturing of respiratory medication, increasing production capacity by 20% with FDA approval of a new production line. It has also donated over 400,000 vials of respiratory products to Americares, a disaster relief nonprofit organization.
Nephron has also begun to manufacture hand sanitizer and has even started administering and processing COVID-19 tests for employees and local businesses to help them get back to work.
Additionally, South Carolina Governor
Henry McMaster named Nephron CEO
Lou Kennedy to the state’s COVID-19 Advisory and Recovery team,
which will make recommendations
regarding economic revitalization
plans in the aftermath of COVID-19.
How Nephron Pharmaceuticals Corporation